{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:48:37Z","timestamp":1783406917857,"version":"3.54.6"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jaad.2018.02.074","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T09:48:19Z","timestamp":1521366499000},"page":"104-109.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3"],"prefix":"10.1016","volume":"79","author":[{"given":"Alexander","family":"Egeberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jashin J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orin","family":"Goldblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotus","family":"Mallbris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2018.02.074_bib1","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/jdv.12350","article-title":"Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis","volume":"28","author":"Strohal","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.02.074_bib2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: a population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.02.074_bib3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.clindermatol.2007.08.012","article-title":"Immunopathogenesis and role of T cells in psoriasis","volume":"25","author":"Ghoreschi","year":"2007","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.02.074_bib4","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.02.074_bib5","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1600-0625.2011.01308.x","article-title":"A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis","volume":"20","author":"Armstrong","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.02.074_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.02.074_bib7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2018.02.074_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.jaad.2018.02.074_bib9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2016.09.026","article-title":"Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data","volume":"76","author":"Strober","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.02.074_bib10","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-2133.2011.10257.x","article-title":"Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies","volume":"164","author":"Reich","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.02.074_bib11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/ard.2008.101964","article-title":"Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions","volume":"68","author":"Choy","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2018.02.074_bib12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/jid.2013.359","article-title":"Anti-psoriatic therapy recovers high-density lipoprotein composition and function","volume":"134","author":"Holzer","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.02.074_bib13","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1161\/01.CIR.96.8.2520","article-title":"Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction","volume":"96","author":"Gaziano","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jaad.2018.02.074_bib14","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jdv.14200","article-title":"Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis\u2014nationwide results from the DERMBIO registry","volume":"31","author":"Egeberg","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.02.074_bib15","doi-asserted-by":"crossref","first-page":"AB43","DOI":"10.1016\/j.jaad.2017.04.187","article-title":"Analysis of major adverse cardiovascular events (MACE) among patients treated with biologics in the Psoriasis Longitudnal Assessment and Registry Study (PSOLAR)","volume":"76","author":"Bissonnette","year":"2017","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218303682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218303682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:45:00Z","timestamp":1759272300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218303682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0190962218303682"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.02.074","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.02.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}